RLYB Stock Overview
A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rallybio Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.24 |
52 Week High | US$5.96 |
52 Week Low | US$1.09 |
Beta | -1.69 |
11 Month Change | -8.82% |
3 Month Change | -15.65% |
1 Year Change | -77.86% |
33 Year Change | -90.57% |
5 Year Change | n/a |
Change since IPO | -91.21% |
Recent News & Updates
Recent updates
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully
Aug 28Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
Jan 04Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?
Sep 19Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
May 15We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth
Jan 30Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Oct 31Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Jul 07Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans
Mar 16Shareholder Returns
RLYB | US Biotechs | US Market | |
---|---|---|---|
7D | 11.7% | 0.4% | 0.6% |
1Y | -77.9% | 14.0% | 22.9% |
Return vs Industry: RLYB underperformed the US Biotechs industry which returned 15.8% over the past year.
Return vs Market: RLYB underperformed the US Market which returned 24.9% over the past year.
Price Volatility
RLYB volatility | |
---|---|
RLYB Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RLYB's share price has been volatile over the past 3 months.
Volatility Over Time: RLYB's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 25 | Steve Uden | www.rallybio.com |
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Rallybio Corporation Fundamentals Summary
RLYB fundamental statistics | |
---|---|
Market cap | US$47.30m |
Earnings (TTM) | -US$73.88m |
Revenue (TTM) | US$299.00k |
172.1x
P/S Ratio-0.7x
P/E RatioIs RLYB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RLYB income statement (TTM) | |
---|---|
Revenue | US$299.00k |
Cost of Revenue | -US$450.00k |
Gross Profit | US$749.00k |
Other Expenses | US$74.63m |
Earnings | -US$73.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.78 |
Gross Margin | 250.50% |
Net Profit Margin | -24,709.36% |
Debt/Equity Ratio | 0% |
How did RLYB perform over the long term?
See historical performance and comparison